Optimizing high-dose therapy using pharmacokinetic principles.
The oncologic literature of the past decade contains numerous articles supporting the concept of "dose intensity." The hypothesis that greater intensity of effective drug therapy can result in higher cure rates is supported by the results obtained in bone marrow transplantation for leukemia, lymphoma, and, possibly, breast carcinoma. Stem cell infusion overcomes the first level of the dose-limiting toxicities, ie, bone marrow suppression. This predictable toxicity develops in all patients. Second organ toxicities, such as renal, hepatic, or cardiopulmonary toxicity, occur in a less predictable manner. This variation in individual patient tolerance may be related to wide variations in drug concentration between patients while receiving the same dose. This interpatient variability has been well described for many oncologic agents, but is not unique to oncologic therapy. Important but incompletely defined relationships of importance to high-dose therapy include (1) the relationship of drug dose to concentration within patient groups and for the individual patient and (2) the relationship of drug concentration, or other related parameter such as area under the concentration versus time curve, to toxicity and outcome. Assuming such relationships can be defined, the value of using improved methods to select drug doses for an individual patient to achieve therapeutic goals needs to be explored. The purpose is to optimize therapy. In the bone marrow transplantation setting, the ideal is to provide the greatest drug exposure without undo risk of life-threatening second organ toxicity. To solve these problems, we need models that predict and allow us to control therapy in a much more precise manner than is currently possible. This review examines the concept of dose intensity, defines this concept in terms of plasma drug concentrations, and reviews methods that can aid the control of therapy in the individual patient. The potential importance of this methodology to the individual patient is discussed.
Zorsky
P E
PE
Division of Bone Marrow Transplantation, University of South Florida College of Medicine, Tampa.
Perkins
J B
JB
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents